Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease

Shen, Y.G.; Charlesworth, J. A.; Kelly, John J.; Loi, Ken; Peake, Philip W.

doi:10.1093/ndt/gfl552

Cited by 64 publications

(61 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Decrease in serum adiponectin levels has been reported to be associated with conditions such as insulin resistance, obesity, diabetes mellitus and dyslipidemia (24)(25)(26)(27). However, serum adiponectin levels were not associated with insulin resistance indicated by HOMA score in the present study.…”

Section: Discussioncontrasting

confidence: 72%

Untitled

2014

Turk Neph Dial Transpl

View full text Add to dashboard Cite

ObJeCtIVe: Protein-energy wasting (PEW) and inflammation are common and related to increased cardiovascular mortality in hemodialysis (HD) patients. Herein, we aimed to investigate the relationships between adipocytokines, inflammation and serum and anthropometric markers of PEW syndrome in HD patients. mAterIAl and metHOds: Seventy-four HD patients (mean age=62±13 years, male/female=44/30) were enrolled. Serum leptin, adiponectin and IL-6 levels were measured by ELISA. Anthropometric measurements such as triceps skin fold thickness (TSFT), mid-arm circumference (MAC) were performed. Bioelectrical impedance analysis was also done. The degree of malnutrition was evaluated with subjective global assessment (SGA). results:The leptin/fat ratio was associated with serum IL-6 (r=0.32, p=0.008), serum albumin (r= -0.37, p=0.002) and TSFT (r= -0.41, p=0.001). Serum adiponectin levels were positively correlated with serum albumin (r=0.29,p=0.01) and negatively associated with the leptin/fat ratio (r= -0.30, p=0.01). Serum CRP levels were significantly lower in the high adiponectin group (1.20 ±0.92 vs 2.02 ±2.18 µg/mL, p=0.042). On linear regression analysis for predicting the leptin/fat ratio, gender and serum albumin were retained as significant in the model. bulGulAr: Leptin / yağ oranının serum 32, p=0,008) ve serum albumin (r= -0,37, p=0,002) seviyeleri ve TSFT (r= -0,41, p=0,001) ile ilişkili olduğu görüldü. Serum adiponektin düzeyleri serum albumini (r=0,29, p=0,01) ile pozitif korele ve leptin/yağ oranı (r= -0,30, p=0,01) ile negatif korele bulundu. Yüksek adiponektin düzeyi olan grupta serum CRP düzeyleri anlamlı olarak düşük bulundu (1,20 ± 0,92 vs 2,02 ± 2,18 µg/mL, p=0,042). Modelde leptin /yağ oranının prediktif değeri için yapılan lineer regresyon analizinde cinsiyet ve serum albümin değeri anlamlı kalmaya devam etti. türk nefroloji diyaliz ve transplantasyon dergisi Turkish Nephrology, Dialysis and Transplantation Journal

show abstract

Section: Discussioncontrasting

confidence: 72%

Untitled

2014

Turk Neph Dial Transpl

View full text Add to dashboard Cite

show abstract

“…Second, we found an association of plasma HMW adiponectin levels and HMW-to-total adiponectin ratio with the use of RAS inhibitors and CCBs in hemodialysis patients. Several investigators have reported that total adiponectin levels are higher in patients on hemodialysis compared with healthy volunteers 6,[12][13][14] and those with pre-hemodialysis CKD. 15 In this study, HMW adiponectin levels were significantly higher in hemodialysis patients compared with patients with CKD in both men and women.…”

Section: Discussionmentioning

confidence: 99%

“…Zoccali et al 6 suggested that the downregulation of adiponectin receptors may reset serum adiponectin concentrations to a higher level. Recently, Shen et al 12 reported that both AdipoR1 and R2 upregulated peripheral blood mononuclear cells of hemodialysis patients in a manner unrelated to insulin resistance, suggesting that adiponectin signaling is an adaptive, protective mechanism in uremia rather than a cause of dysmetabolism. However, it is clear that hemodialysis patients have a high risk of atherosclerotic disease, despite hyperadiponectinemia.…”

Section: Discussionmentioning

confidence: 99%

Potential impact of renin–angiotensin system inhibitors and calcium channel blockers on plasma high-molecular-weight adiponectin levels in hemodialysis patients

Nakagawa

Yao²,

Hirayama³

et al. 2011

Hypertens Res

View full text Add to dashboard Cite

Although metabolic syndrome confers an increased risk of cardiovascular disease in the general population, little is known about the alteration of abdominal adiposity and its association with adipocytokines in hemodialysis patients. We investigated the plasma high-molecular-weight (HMW) adiponectin level and its relationship to visceral fat area (VFA) and various markers of atherosclerosis in hemodialysis patients. In a cross-sectional study, conventional cardiovascular risk factors, plasma total and HMW adiponectin, the number of components of the metabolic syndrome and, using computed tomography, the distribution of abdominal adiposity were assessed in 144 hemodialysis patients (90 men and 54 women; mean age, 60.7 years) and 30 age-and sex-matched patients with chronic kidney disease (CKD). Plasma HMW adiponectin levels in hemodialysis patients were significantly higher than those in patients with CKD, negatively associated with VFA and serum triglycerides and positively associated with plasma total adiponectin, as well as the HMW-to-total adiponectin ratio in men and women (all Po0.05) in a simple regression analysis. In a multiple regression analysis, VFA was a significant determinant of HMW adiponectin in hemodialysis patients. Furthermore, after adjustment for classical risk factors, HMW adiponectin levels were significantly higher in patients undergoing treatment with renin-angiotensin system inhibitors or calcium channel blockers compared with patients not undergoing such treatment. This study shows that plasma HMW adiponectin levels were negatively associated with VFA and positively associated with treatment with blockade of the renin-angiotensin system and of the calcium channel. Therefore, these drugs might be effective for improving adipocytokine-related metabolic abnormalities in hemodialysis patients.

show abstract

“…63, 64 Shen and colleagues found that in ESRD patients there is an increased proportion of the HMW moiety and that the adiponectin/receptor system appears to be up-regulated in ESRD, possibly as an appropriate counter-regulatory response to the uremic milieu. 39 However, a recent study by Giers and coworkers found no relationship between insulin resistance and adiponectin concentration, including total adiponectin concentration, the concentration of HMW adiponectin and its percentage in total adiponectin. 65 On the other hand, hyperadiponectinemia, associated with the inability to lower plasma glucose levels and blunted hepatic AMPK response to adiponectin, delineates a condition of adiponectin resistance.…”

Section: Adiponectin and Insulin Resistance In Esrdmentioning

confidence: 96%

“…Moreover, levels of the HMW isoform are also elevated in ESRD, although the distribution of all the adiponectin isoforms in ESRD has not thus far been well studied. 39 Serum adiponectin levels are significantly lower in males than in females, in patients with obesity, insulin resistance, type 2 diabetes mellitus, coronary artery disease and essential hypertension. [40][41][42][43][44] Adiponectin levels correlate significantly with several metabolic factors.…”

Section: Circulating Adiponectin Levels In Esrd Patientsmentioning

confidence: 99%

Adiponectin and end-stage renal disease

Markaki¹,

Psylinakis²,

Spyridaki³

2016

View full text Add to dashboard Cite

Adiponectin (ADPN) is an adipokine with significant anti-inflammatory, insulin-sensitizing and anti-atherogenic properties, which is generally associated with a beneficial cardiometabolic profile. Paradoxically, end-stage renal disease (ESRD) is characterized by markedly increased plasma ADPN levels and increased cardiovascular risk. In spite of the cardioprotective properties attributed to adiponectin, cardiovascular complications remain the main cause of mortality in the ESRD population. Furthermore, these patients have enhanced chronic inflammation, increased insulin resistance and persistent protein-energy wasting. Studies of the impact of ADPN on clinical outcomes among ESRD patients have so far yielded contradictory results. This review article summarizes the current knowledge on ADPN functions and explores the role of ADPN in ESRD patients, with specific focus on inflammation, insulin resistance, cardiovascular disease and wasting.

show abstract

Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease

Abstract: IR in ESKD is not explained by the change in isoformic distribution, or by AdipoR down-regulation or dysfunction. Rather, this receptor-ligand axis is up-regulated and may be a beneficial response to the inflammatory milieu of ESKD.

Cited by 64 publications

References 22 publications

Untitled

Untitled

Potential impact of renin–angiotensin system inhibitors and calcium channel blockers on plasma high-molecular-weight adiponectin levels in hemodialysis patients

Adiponectin and end-stage renal disease

Contact Info

Product

Resources

About